公开(公告)号：US20210032252A1

公开(公告)日：2021-02-04

申请号：US16966708

申请日：2019-01-29

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  Thomas P. Bobinski ,  Aaron Craig Burns ,  Nidhi Arora ,  James Gail Christensen ,  John Michael Ketcham

IPC: C07D487/04

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20180127369A1

公开(公告)日：2018-05-10

申请号：US15725949

申请日：2017-10-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Arkadii Vaisburg ,  James Gail Christensen ,  Robert Anthony Galemmo, JR.

IPC: C07D211/58 ,  C07D213/64 ,  C07D413/14 ,  C07D413/12 ,  C07D401/12 ,  C07D417/12 ,  C07D205/04 ,  C07D211/76 ,  C07D221/22 ,  C07D265/10 ,  C07D211/88

CPC classification number: C07D211/58 ,  C07D205/04 ,  C07D211/76 ,  C07D211/88 ,  C07D213/64 ,  C07D221/22 ,  C07D265/10 ,  C07D401/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20250108055A1

公开(公告)日：2025-04-03

申请号：US18906104

申请日：2024-10-03

Applicant: Mirati Therapeutics, Inc.

Inventor： Ruth Wei Aranda ,  James Gail Christensen ,  Lars Daniel Engstrom ,  Jill Hallin ,  Peter Olson

IPC: A61K31/519 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US12171765B2

公开(公告)日：2024-12-24

申请号：US17713455

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/506 ,  A61P35/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.

公开(公告)号：US20240408099A1

公开(公告)日：2024-12-12

申请号：US18694867

申请日：2022-10-04

Applicant: MIRATI THERAPEUTICS, INC.

Inventor： Jill Hallin ,  James Gail Christensen ,  Vickie Bowcut ,  Peter Olson

IPC: A61K31/519 ,  A61K31/517 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12D cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US12128048B2

公开(公告)日：2024-10-29

申请号：US17713472

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/416 ,  A61K31/502 ,  A61K31/517 ,  A61P35/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/517 ,  A61K2300/00 ,  A61K31/502 ,  A61K2300/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.

公开(公告)号：US20230077225A1

公开(公告)日：2023-03-09

申请号：US17869575

申请日：2022-07-20

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20220331324A1

公开(公告)日：2022-10-20

申请号：US17713472

申请日：2022-04-05

Applicant: Mirati Therapeutics, Inc.

Inventor： Lars Daniel Engstrom ,  Peter Olson ,  James Gail Christensen

IPC: A61K31/519 ,  A61K31/517 ,  A61K31/416 ,  A61K31/502 ,  A61P35/00

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.

公开(公告)号：US20220079947A1

公开(公告)日：2022-03-17

申请号：US17275181

申请日：2019-12-05

Applicant: Mirati Therapeutics, Inc.

Inventor： James Gail Christensen ,  Lars Daniel Engstrom ,  Peter Olson ,  Ruth Wei Aranda

IPC: A61K31/519 ,  A61P35/00 ,  A61K31/497

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.

公开(公告)号：US20220054492A1

公开(公告)日：2022-02-24

申请号：US17275178

申请日：2019-09-10

Applicant: Mirati Therapeutics, Inc.

Inventor： Ruth Wei Aranda ,  James Gail Christensen ,  Lars Daniel Engstrom ,  Jill Hallin ,  Peter Olson

IPC: A61K31/519 ,  A61K31/44 ,  A61K31/506 ,  A61K31/4375 ,  A61K31/5377 ,  A61K31/428 ,  A61K31/517 ,  A61K31/4985 ,  A61P35/00

Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.